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free survival (PFS) and/or overall survival (OS) as reported outcomes and to create 
a RCT network accordingly. Fixed and random effects FP models of first/second 
order were applied on these data and tested for goodness of fit using deviance 
information criteria. Finally, the best fitting model was used to estimate the hazard 
function, median PFS, median OS and uncertainty of treatment effect. Results: 
Literature review found 8 RCTs and 5 RCTs which reported PFS and OS respec-
tively, for 7 different mRCC treatments (interferon-alfa (IFN), bevacizumab+IFN, 
temisrolimus+bevacizumab, sunitinib, pazopanib, cediranib, placebo). The best fit-
ting FP model was second order random effect model for both, PFS and OS NMA. 
Hazard functions varied significantly. Estimated median PFS was the longest with 
sunitinib (10.8 months; 95% credible interval (CI): 9.5-11.8), followed by pazopanib 
and temsirolimus+bevacizumab. Similarly, sunitinib was estimated with the 
longest median OS (28.8 months; 95% CI: 25.7-31.0) followed by pazopanib and 
bevacizumab+IFN. ConClusions: Synthesis of NMA evidence for 1LmRCC treat-
ments identified sunitinib to be the treatment with favourable PFS and OS. When 
dealing with multiple sources, hazards proportionality assumption is violated, and 
proposed method should be the method of choice.
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objeCtives: Network meta-analysis (NMA) is widely used to compare multiple 
interventions of interest when head-to-head comparisons of active treatments are 
not available. Most NMAs pool data from randomised controlled trials (RCTs) on a 
single clinical outcome. However, in the case of chronic diseases such as rheumatoid 
arthritis (RA), outcomes are often reported at different time points and long-term 
real-world data (RWD) is routinely collected as part of national registries. Evaluation 
of models for the inclusion of different time measures in NMA, especially from both 
a regulatory and reimbursement perspective, is thus warranted and is considered 
here. Methods: RCTs and observational studies evaluating biological agents in RA 
were searched using standard filters and electronic databases. Networks of RCTs 
were supplemented with RWD to include outcomes extracted for as many time 
points as possible. Multivariate NMA models were extended to incorporate repeated 
measures, adjusting for correlation between time points and bias of RWD. Sensitivity 
and scenario analyses were performed to test different network sizes, correlation 
structures and bias adjustments. Results: Addition of RWD and studies reporting 
treatment effects at multiple time points significantly increased the evidence base 
for NMA in RA. The inclusion of RWD led to a reduction in the level of uncertainty 
around most of the effect estimates. Furthermore, the additional evidence from 
multiple times has potential of reducing uncertainty by ‘borrowing’ evidence and 
giving a fuller view of treatment effect over time, not just at a specific single time 
point. ConClusions: Initial evaluation of these models in NMA indicates that 
extending an evidence base to include repeated measures and RWD maximises 
study network sizes and can significantly impact the level of uncertainty in treat-
ment effects. Further investigation of correlation and bias modelling is warranted, 
as too is the application of new NMA fractional polynomials model to RA.
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objeCtives: Using simulated annealing (SA) to inform the economic evaluation 
of treatment sequences for rheumatoid arthritis (RA). Methods: A discrete event 
simulation (DES) model was built to estimate lifetime costs and Quality Adjusted 
Life Years (QALYs) of alternative sequences for the treatment of patients with 
severe RA. Thirteen Disease Modifying Anti-Rheumatic Drugs (DMARDs) can be 
used sequentially, with a theoretical maximum size of the decision space of over 
10 billion unique sequences. This problem can be formulated as an optimisation 
problem – finding the treatment sequence that maximises net monetary benefit 
(NMB). However, it was not feasible to evaluate the NMB of every treatment sequence 
in the decision space. SA, a stochastic optimisation algorithm, was used to identify 
a sequence that was optimal, or near optimal. Given the evaluation of the NMB 
of some particular sequence by the DES model , the SA algorithm then selects a 
“nearby” sequence to evaluate. Better solutions are accepted, and worse solutions 
are sometimes accepted with a probability reducing as the algorithm progresses. 
This attempts to prevent the optimiser from getting stuck in a local optimum. 
Comprehensive tuning of the parameters of the SA algorithm was undertaken, 
and scenario analysis was performed. Results: At a willingness to pay of £30,000 
per QALY gained, the best performing sequence found was exclusively composed of 
conventional DMARDs. At £50,000 per QALY gained, the best performing sequence 
began with conventional DMARDs for the first four treatment lines, before beginning 
biologic DMARD treatment. The results were consistent when re-run, and when 
alternative specifications of the SA algorithm were used. ConClusions: SA is a 
commonly used optimisation method, but it has rarely been applied in HTA. In this 
instance, SA performed well and may be an appropriate method for health resource 
allocation decision-making where there is a large decision space.
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objeCtives: The aim of this study is to compare the usefulness of two prom-
ising alternative modeling techniques, Timed Automata (TA) originating from 
65. Similarly, a 5-point lower MCS score among those with depression was associated 
with a 10% increase in MEs at age 25 but 4% at age 55. ConClusions: Differences in 
SF-12v2 scores, particularly PCS, had substantial impact on MEs, allowing enhanced 
interpretation of intervention-based improvements in SF-12v2 scores. In arthritis 
and depression, age significantly impacted the association between HRQL and MEs.
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objeCtives: Perceived and observed insensitivity of the EQ-5D instrument in cer-
tain clinical areas has led to the development of condition specific preference based 
instruments, also for Multiple Sclerosis (MS). It is uncertain how these instruments 
perform in economic evaluations. This study investigates the effect on the incre-
mental cost-effectiveness ratio (ICER) of using MS specific utility values rather than 
generic utility values. Methods: A Markov model with a lifetime time horizon 
comparing symptom management with subcutaneous glatiramer acetate was based 
on a previously published study. The model has four EDSS health states and two 
relapse states, a one month cycle, accounts for age specific background mortality 
and discontinuation of therapy. Costs and effects were discounted with 3%. For 
this study, QALYs were calculated with utility values from the MSIS-PBM, a sensi-
tive condition specific utility instrument based on a Time Trade-off valuation of 
MSIS-29, and EQ-5D utility values. Values were both taken from the UK risk sharing 
scheme. Deterministic and Monte Carlo simulation based probabilistic sensitivity 
analyses were used to assess impact on ICER. Results: The mean ICER after 5000 
simulations was USD 291.545 using MS specific utilities, and 180.633 using EQ-5D 
based utilities. ConClusions: This study used condition specific and generic util-
ity values in a hypothetical Markov model for relapsing remitting MS patients and 
showed that the incremental cost-effectiveness ratio was 60% higher when applying 
the condition specific utilities. Contrary to what might be expected, the condition 
specific utility instrument was not better at demonstrating treatment value than 
the generic EQ-5D.
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objeCtives: Adherent type 2 diabetes (T2DM) patients are more likely to have 
good glycaemic control than non-adherent patients, potentially resulting in bet-
ter outcomes. We investigated the association between the number of glucose-
lowering therapies, adherence and their impact on glycaemic control and quality 
of life (QoL). Methods: Data were drawn from the 2013 Diabetes Disease Specific 
Programme, a large cross-sectional real-world survey of primary care physicians 
(PCP) and specialists and their patients consulting for diabetes. Physicians pro-
vided information regarding prescriptions, previous treatment and most recent 
HbA1cvalues. Patients completed the Morisky Measurement of Adherence Scale 
and the EQ-5D. Patients who had been on current treatment between 6 months and 
5 years and had values for all variables were included. A linear Structural Equation 
Model was developed to explore the relationships between the number of oral and 
injectable diabetes medications per day, adherence, glycaemic control and QoL 
while adjusting for confounding factors relating to duration and type of medica-
tion, existing complications, concomitant conditions, demographic and lifestyle 
factors. Results: 239 PCPs and 137 specialists across 5 EU countries provided data 
on 1209 T2DM patients. 58% patients were male, mean age 60.7 years (+/-10.3); num-
ber of oral medications 2.21 (+/-1.16); injectables 0.36 (+/-1.03); current HbA1c6.94% 
(+/-0.80). The model shows that a lower number of daily diabetes medications is 
positively associated with adherence [orals (β = -0.10, p< 0.001), injectables (β = -0.049, 
p< 0.001)]. Improved adherence is associated with a lower HbA1c (β = -0.10, p< 0.001), 
lower HbA1cis associated with improved QoL (β = -0.019, p< 0.001). ConClusions: 
Controlling for important clinical and demographic factors, a lower number of daily 
glucose-lowering therapies is associated with greater adherence which, in turn, is 
associated with better glycaemic control and improved QoL. Further research is 
required to investigate if these associations vary depending on the specific medica-
tion taken or other patient-related parameters not considered here.
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objeCtives: Summary survival data are available from published trials on first line 
metastatic renal cell cancer (1LmRCC) treatments. Survival on oncological treat-
ments in pharmacoeconomics is mainly estimated by fitting common parametric 
distributions over Kaplan Meier (KM) curves, assuming proportional hazards over 
time. Use of fractional polynomials (FP) allows for change of hazards over time and 
offers more freedom in distribution selection. This study aims to analyse exist-
ing survival data of 1LmRCC treatments through a network meta-analysis (NMA) 
and FP application. Methods: A systematic literature review was performed to 
identify randomized clinical trials (RCT) of 1LmRCC treatments with progression 
